Another study including clinical and radiomics variables extracted from PET and CT (51) from 539 patients with confirmed lung adenocarcinomas investigated the potential of differentiating the ALK/ROS1/RET fusion-positive and fusion-negative adenocarcinomas, building a model that resulted in 73% sensitivity and 70% specificity with seven features. The gene discussed is ALK; the disease is lung adenocarcinoma.